Specifically, acute gastroenteritis was reported in 44 patients receiving SGLT-2 inhibitors and 48 control patients (HR, 0.97 [95% CI, 0.64-1.46]; E-value, 1.41), while osteoporosis occurred in 74 patients receiving SGLT-2 inhibitors compared with 71 patients in the control group (HR, 1.09 [95% CI, 0.79-1.51]; E-value, 1.25). This evidence concerns the gene SLC5A2 and osteoporosis.